Article
Pembrolizumab-associated eosinophilic polyserositis with pericardial involvement during adjuvant therapy for clear cell renal cell carcinoma: a case report and narrative review
2026-03-08
Abstract excerpt
<title>Abstract</title> <p> <bold>Background</bold> : Pembrolizumab is a standard adjuvant option for patients with high-risk clear cell renal cell carcinoma after nephrectomy. Serositis is an uncommon immune-related adverse event under programmed cell death 1/programmed death ligand 1 blockade. Pericardial involvement is the best-characterized serosal compartment, and cohort data suggest a several-fold increas...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 9463250a-7e9d-5d70-bb8e-59e4ee694dcb
- DOI
- 10.21203/rs.3.rs-8910623/v1
